VanEck Biotech Financial Statements From 2010 to 2025
| BBH Etf | USD 164.34 1.68 1.03% |
Check VanEck Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among VanEck Biotech's main balance sheet or income statement drivers, such as , as well as many indicators such as . VanEck financial statements analysis is a perfect complement when working with VanEck Biotech Valuation or Volatility modules.
VanEck |
VanEck Biotech ETF ETF Beta Analysis
VanEck Biotech's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current VanEck Biotech Beta | 0.84 |
Most of VanEck Biotech's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VanEck Biotech ETF is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, VanEck Biotech ETF has a Beta of 0.84. This is much higher than that of the VanEck family and significantly higher than that of the Health category. The beta for all United States etfs is notably lower than that of the firm.
VanEck Biotech ETF Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining VanEck Biotech's current stock value. Our valuation model uses many indicators to compare VanEck Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across VanEck Biotech competition to find correlations between indicators driving VanEck Biotech's intrinsic value. More Info.VanEck Biotech ETF is second largest ETF in price to earning as compared to similar ETFs. It is third largest ETF in price to book as compared to similar ETFs fabricating about 0.16 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for VanEck Biotech ETF is roughly 6.45 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the VanEck Biotech's earnings, one of the primary drivers of an investment's value.About VanEck Biotech Financial Statements
Investors use fundamental indicators, such as VanEck Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although VanEck Biotech's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
The fund normally invests at least 80 percent of its total assets in securities that comprise the funds benchmark index. Vaneck Biotech is traded on NASDAQ Exchange in the United States.
Currently Active Assets on Macroaxis
When determining whether VanEck Biotech ETF offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VanEck Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vaneck Biotech Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Vaneck Biotech Etf:Check out the analysis of VanEck Biotech Correlation against competitors. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
The market value of VanEck Biotech ETF is measured differently than its book value, which is the value of VanEck that is recorded on the company's balance sheet. Investors also form their own opinion of VanEck Biotech's value that differs from its market value or its book value, called intrinsic value, which is VanEck Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VanEck Biotech's market value can be influenced by many factors that don't directly affect VanEck Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VanEck Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if VanEck Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VanEck Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.